GlobeNewswire

Saniona receives pre-IND feedback from FDA on regulatory path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Share

PRESS RELEASE

October 9, 2020

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO).

Regarding PWS, the FDA’s Division of Psychiatry within the Office of Neuroscience provided additional feedback on conducting a supportive Phase 2b study evaluating multiple doses of Tesomet in adult and adolescent PWS patients. Saniona expects to begin this Phase 2b study in the first half of 2021.

As part of its ongoing discussions with the FDA, Saniona inquired if the planned Phase 2b study could serve as a single pivotal trial supporting approval of Tesomet in PWS. The FDA considered this request and, as Tesomet is a new molecular entity, the agency recommended that Saniona conduct a supportive Phase 2b study prior to initiating a Phase 3 study to confirm the safety and efficacy of the doses intended for commercialization. In addition, in recognition of the significant unmet need within the PWS pediatric population, the FDA recommended that Saniona plan to evaluate Tesomet in children younger than age 12.

Regarding HO, the FDA’s Division of Diabetes, Lipid Disorders and Obesity within the Office of Cardiology, Hematology, Endocrinology, and Nephrology agreed that the 505(b)(2) pathway is an appropriate development pathway for Tesomet. The agency recommended that the clinical development program for Tesomet in HO include a supportive Phase 2b study followed by a Phase 3 study. The agency expressed concerns about potential off-label use in the general obese population and suggested this needs to be evaluated, such as through a cardiovascular outcomes study, or that Saniona would need to clarify how it would restrict distribution of Tesomet exclusively to the rare HO population. Saniona is seeking additional guidance from the FDA in order to clarify the path forward for Tesomet in HO.

Prader-Willi Syndrome and Hypothalamic Obesity are rare diseases that represent significant unmet needs with high caregiver burden, and there are currently no treatments specifically approved for either indication,” said Rami Levin, President and CEO of Saniona. “We now have a clear path forward for the development of Tesomet as a novel treatment for PWS, and we look forward to further engaging with the FDA to clarify the best path for bringing Tesomet to patients suffering from the serious, rare condition HO while avoiding inappropriate use in generally obese patients.”

For more information, please contact

Trista Morrison, Chief Communications Officer. Office + 1 (781) 810-9227. Email: Trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on October 9, 2020.

About Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

About Tesomet

Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

About Prader-Willi Syndrome (PWS)

Prader-Willi syndrome (PWS) is a rare disease characterized by constant, extreme, ravenous, insatiable appetite (hyperphagia) which persists no matter how much the patients eat. The urge to eat is physiological, overwhelming, and difficult to control. Caregivers need to strictly limit the patients' access to food, usually by installing locks on refrigerators and cabinets where food is stored. Many of those affected with PWS become morbidly obese and suffer shortened life expectancy and significant mortality. Common causes of mortality in PWS include respiratory disease, cardiac disease, infection, choking, gastric rupture, and pulmonary embolism. However, if obesity is avoided and complications are well managed, life expectancy for individuals with PWS is normal or near normal, and most individuals can lead healthy lives. Currently, there is no cure for this disease. PWS results from a deletion or loss of function of a cluster of genes on chromosome 15, which leads to dysfunctional signaling in the brain’s appetite/satiety center (hypothalamus). PWS occurs in approximately one out of every 15,000 births.

About Hypothalamic Obesity (HO)

Hypothalamic obesity (HO) is a rare disorder characterized by uncontrollable hunger leading to rapid and intractable weight gain. Additional symptoms may include memory impairment, attention deficit, impulse control and depression as well as increased risk of cardiovascular and metabolic disorders. Currently, there is no cure for this condition. Treatments used for general obesity such as surgery, medication and counseling are often tried in HO, but are mostly ineffective, and there are no medications specifically approved for HO. HO is caused by injury to the hypothalamus, most commonly sustained during surgery to remove a rare, noncancerous tumor called a craniopharyngioma. This tumor can occur at any age, but is most common in children and older adults, creating a burden for both patients and families. HO occurs in approximately one out of every 50,000 to 100,000 people.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Auriant Mining Q3 2020 Interim Report and Online Conference, November 30th 202025.11.2020 11:19:11 CETPress release

Auriant Mining AB is pleased to announce that the Company’s Q3 2020 interim report will be published on Monday, November 30th. This will be followed by a live ZOOM Video Conference for analysts and investors with Danilo Lange (CEO), Vladimir Vorushkin (CFO) and Petr Kustikov (COO from December 1st 2020), who will be presenting Auriant Mining’s Q3 2020 results as well as hosting a Q&A session. The event will begin at 12:00 CET (12:00 Stockholm, 14:00 Moscow, 11:00 London). To participate in the ZOOM Video Conference on Monday, November 30th, please send to our email conf@auriant.com the following information: email, name, Company name. We will send the conference ID and passcode by email. If you have any questions, you can send them to our email: conf@auriant.com. For more information, please contact: Danilo Lange, CEO Tel: +7 495 109 02 82 E-mail: d.lange@auriant.com Company name: Auriant Mining AB Short name: AUR ISIN-code: SE0001337213 Website: www.auriant.com www.facebook.com/Aurian

Auriant Mining:s delårsrapport för Q3 2020 och online-konferens den 30 november 202025.11.2020 11:19:11 CETPressemelding

Auriant Mining AB har nöjet att meddela att Bolagets delårsrapport för Q3 2020 kommer att publiceras på måndagen den 30 november. Detta kommer att följas av en live ZOOM-videokonferens för analytiker och investerare med Danilo Lange (VD), Vladimir Vorushkin (Ekonomichef) and Petr Kustikov (Operativ chef från den 1 december 2020), som kommer att presentera Auriant Mining:s resultat för Q3 2020 samt med en möjlighet att ställa frågor. Evenemanget börjar kl. 12:00 CET (12:00 Stockholm, 14:00 Moskva, 11:00 London). För att delta i ZOOM-videokonferensen måndagen den 30 november, vänligen skicka till e-post conf@auriant.com följande uppgifter: e-post, namn, företagsnamn. Vi kommer att skicka konferens-ID och lösenord via mail. Om du har några frågor kan du skicka dem till e-post: conf@auriant.com För mer information, vänligen kontakta: Danilo Lange, VD Tel: +7 495 109 02 82 E-post: d.lange@auriant.com Företagsnamn: Auriant Mining AB Kortnamn: AUR ISIN-kod: SE0001337213 Webbplats: www.auriant

Auriant Mining AB (publ.) tillkännager utnämning av Petr Kustikov till Operativ chef25.11.2020 11:10:09 CETPressemelding

Styrelse för Auriant Mining AB (publ.) (Bolaget) har nöjet att tillkännage utnämningen av Petr Kustikov till Operativ chef med verkan från och med den 1 december 2020. Petr har varit chef för projektutveckling på Auriant sedan 2016 och spelat en ledande roll i konstruktion av den framgångsrika CIL-anläggningen vid Tardan-fyndigheten. Han är en erfaren gruvchef och arbetade i den rollen på både Oxus Gold och Orsu Metals. Petr tog examen från Navoi statliga gruvinstitut med en examen inom gruvteknik och har avslutat sin magisterexamen i företagsekonomi från Plekhanov ryska ekonomiska universitet, Moskva. Petr är medlem i Australasian gruv- och metallurgiskt institut sedan 2014. Omedelbart innan han gick med i Auriant var han en ledande konsult på SRK Consulting (Ryssland) med säte i Moskva. Danilo Lange, verkställande direktör, kommenterade: ” Vi är mycket glada att Petr har accepterat denna utnämning, som kommer att övervaka hela koncernens verksamhet, inklusive den pågående produktione

Auriant Mining AB (publ.) Appointment of Petr Kustikov as Chief Operating Officer25.11.2020 11:10:09 CETPress release

The Board of Directors of Auriant Mining AB (publ.) (the “Company”) is pleased to announce the appointment of Petr Kustikov as Chief Operating Officer with effect from 1 December 2020. Petr has been Head of Project Development at Auriant since 2016, and played a leading role in the construction of the successful CIL plant at the Company’s Tardan mine. He is an experienced mine manager, having worked in that role at both Oxus Gold and Orsu Metals. Petr graduated from Navoi State Mining Institute with a degree in Mining Engineering and has completed his Master in Business Administration from the Plekhanov Russian University of Economics, Moscow. Petr has been a member of the Australasian Institute of Mining and Metallurgy since 2014. Immediately prior to joining Auriant he was a Leading Consultant at SRK Consulting (Russia) based in Moscow. Danilo Lange, Chief Executive, said: “We are delighted that Petr has accepted this appointment, which will oversee all the Group’s operations, includ

Arcoma presenterar på Erik Penser Banks bolagsdag idag 25 november klockan 13:5025.11.2020 10:45:00 CETPressemelding

2020-11-25 PRESSRELEASE Arcoma presenterar på Erik Penser Banks bolagsdag idag 25 november klockan 13:50 Arcoma presenterar på Erik Penser Banks bolagsdag idag den 25 november klockan 13:50 2020 då Arcomas nya VD, Sanna Rydberg berättar om bolaget samt deltar på intervju. Presentationen livestreamas på Erik Pensers YouTubekanal, Penser Play: https://www.youtube.com/watch?v=ofEBURUzoxc Inspelad presentation och intervju kommer även läggas upp på Erik Penser banks digitala kanaler. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av

Result of Riksbank´s purchases of Commercial Paper25.11.2020 10:00:00 CETPress release

Auction date201125 Requested volume, SEK mln4,000 Credit rating class1Term3MFixed purchase rate0.45 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class1Term6MFixed purchase rate0.55 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class2Term3MFixed purchase rate0.75 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0 Credit rating class2Term6MFixed purchase rate0.85 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted0.00 %Number of bids0